|
AU2005200354C1
|
|
N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
|
|
ZA200208350B
|
|
Administration of a thiol-based chemoprotectant compound.
|
|
CA2410056A1
|
|
Induction of apoptosis and cell growth inhibition by protein 4.33
|
|
US2001041928A1
|
|
Endovascular stent graft
|
|
AU5391901A
|
|
Administration of a thiol-based chemoprotectant compound
|
|
AU1355501A
|
|
Modulation of neuroendocrine differentiation by protein 25.1
|
|
WO0132925A1
|
|
Modulation of neuroendocrine differentiation by protein 25.1
|
|
AU5344900A
|
|
Mammalian melanocortin receptor agonists and antagonists for modulating feeding behavior in animals
|
|
US7396810B1
|
|
Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
|
|
WO0046361A1
|
|
Inhibition of the mhc class ii antigen presentation pathway and presentation to cd4+ cells
|
|
US6558911B1
|
|
Sperm quality assay
|
|
AU1344700A
|
|
Cloning of rhadinovirus genome and methods for its use
|
|
WO0033884A1
|
|
Conjugates of lipids and antimicrobial or antineoplastic drugs
|
|
AU3553199A
|
|
Enhancement of cellular gallium uptake
|
|
AU3484499A
|
|
Reagents and methods for inhibiting furin protease activity
|
|
CA2320136A1
|
|
Treatment of bony defects with osteoblast precursor cells
|
|
AU1628799A
|
|
Covalent polar lipid conjugates with antimicrobial and antineoplastic drugs for targeting to biological protected sites
|
|
US6541214B1
|
|
N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
|
|
EP1024806A1
|
|
Use of non-immunosuppressive compounds for promoting nerve regeneration
|
|
AU9599398A
|
|
Methods of replicating virus in monocyte-derived macrophage cultures
|
